ArticleJugan geon-gang gwa jilbyeong2025
[Analysis of Adenovirus Detection Trends in the Republic of Korea (2023-2024)].
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resurgence of Human Adenovirus Infections in the Korean Military Following the COVID-19 Pandemic.Journal of Korean medical science · 2026Article
- Seasonal dynamics and genetic diversity of human adenoviruses in patients with acute respiratory infection in Thailand, 2024.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to assess the prevalence and serotype distribution of adenovirus in the Republic of Korea (ROK) by analyzing detection rates and identifying the predominant circulating serotypes. Methods: Through the Korea Respiratory viruses Integrated Surveillance System, real-time polymerase chain reaction testing was performed on 33,688 respiratory specimens collected from symptomatic individuals in ROK between January 2023 and December 2024. Detection rates of adenovirus were analyzed, and selected positive samples-stratified by age group-were further examined via nucleotide sequencing to determine serotype distribution. Results: The average adenovirus detection rates in 2023 and 2024 were 14.8% and 5.8%, respectively. A significant increase in detection rates was observed from summer to autumn in 2023, peaking at 42.4% during weeks 29 to 33, followed by a gradual decline. By 2024, detection rates decreased and remained below 10%. Age-stratified analysis revealed a higher detection rate among individuals aged 0-12 years, with the highest rate (27.5%) observed in the 0-6 years subgroup. Serotyping revealed serotype 3 as the most prevalent, accounting for 36.0% of cases, followed by serotypes 2, 1, and other subtypes. Significantly, serotype 3 predominated during the summer and autumn of 2023. Additionally, serotype 14, previously unreported in the community, was consistently detected throughout 2024. Conclusions: This analysis suggests that the unusual increase in adenovirus detection during the summer of 2023 may have been driven by an outbreak of serotype 3 and highlights the importance for close monitoring for potential clinical changes following the identification of a new serotype, type 14. Accordingly, the national surveillance system will continue to operate to enhance our understanding of respiratory infectious disease trends and to support effective responses, providing data on pathogen detection patterns and characteristic analyses, including serotype identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.